RudaCure (CEO Yongho Kim), una empresa biotecnológica especializada en el desarrollo de nuevos fármacos, anunció el 3rd that it ha sido seleccionada para the 2025 Agri-Food Venture Development Support Program organized by the Ministry of Agriculture, Food and Rural Affairs, and will commence full-scale desarrollo of a veterinario gene-based tratamiento del dolor.
The 'Agri-Food Venture Development Support Program' is a gobierno apoyo programa defirmó to discover and nurture prometedor ventures and startups that will drive high value-añadió crecimiento in the agri-food industria. Each year, it selects prometedor proyectos through rigorous evaluación with the aim of creating future food sources and industrial competitiveness in the agricultural and livestock sectors based on innovador tecnología.
Este proyecto tiene como objetivo develop a terapia génica that induces analgésico no narcótico effects for application in dolor crónico management of animal de compañías and high-value animals such as racehorses. RudaCure has aseguró innovador tecnología that achieves long-term alivio del dolor with a single administration using its proprietary dirigido a canales iónicos peptide delivered via AAV (Adeno-Associated Virus) vectors.
Según RudaCure, preliminary test resultados show that the tratamiento provides continuous efectos analgésicos for more than 3 months with just a single administration. The global veterinario tratamiento del dolor mercado is growing rapidly at aproximadamente $2 billion por año, and there is rising demand for innovador tratamientos that move beyond existing NSAIDs and opioid-based drugs.
El CEO Kim declaró: "Being seleccionada for this apoyo programa is reconocimiento of the innovador tecnología we have accumulated in the veterinario terapia génica field. A través de esto proyecto, we will accelerate the desarrollo of veterinario tratamiento del dolors and advance into the mercado global."
